Follow the Money: MabVax Therapeutics, Inc.


Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

MabVax Therapeutics, Inc. is a U.S. public pharmaceutical company that develops human antibody-based anti-cancer drugs and cancer diagnostic products. As reported in the October 8, 2015 issue of the PharmSource Lead Sheet, MabVax Therapeutics raised $2.75 million in the completion of a secondary public offering.

Corporate Highlights

  • MabVax Therapeutics was originally incorporated in Delaware in 1988 under the name Terrapin Diagnostics, Inc.
  • Corporate Headquarters: San Diego, California – approximately 5,955 square feet of office space.
  • As of March 31, 2015, MabVax Therapeutics had 12 employees.

Sourcing Opportunities

  • MabVax Therapeutics plans to use the proceeds for working capital and general purposes, as well as for product development, including:
    • HuMab 5B1: Complete Phase I study:
      • For the treatment of pancreatic and colon cancer
      • Dosage Form: Parenteral
      • Nature of API: Biologic – Monoclonal antibody
      • Therapeutic Area: Oncology – Immunotherapy
  • The company contracts with contract research organizations (CROs) to conduct clinical trials.
  • MabVax Therapeutics does not own or operate manufacturing facilities and has no plans to develop them. The company relies on third party contract manufacturers for all required raw materials, API, and finished product for preclinical studies and clinical trials.
  • MabVax Therapeutics has no sales, marketing or distribution experience.

Business Relationships

  • On August 29, 2014, MabVax Therapeutics entered into agreements with Memorial Sloan Kettering Cancer Center (MSKCC) and Juno Therapeutics for the development of novel therapeutic products using unique antibody targeting sequences derived from MabVax-discovered fully-human antibodies. MabVax and Juno entered into an exclusive option agreement giving Juno the right to negotiate a license agreement for exclusive rights to any CAR T-cell therapeutic products using the antibody sequences provided to MSKCC. Financial terms were undisclosed.
  • On October 15, 2015, MabVax Therapeutics entered into a license agreement with Thermo Fisher Scientific for the CHO Cell Line for manufacturing the HuMab 5B1 antibody. The agreement allows MabVax to use the Cell Line for internal research, clinical testing, and commercial protein production of its antibodies in applications covering therapeutic and diagnostic areas. Financial terms were undisclosed.


Product Candidate Indication Dosage Form Status Next Anticipated Step
1B7/31F9 Sarcoma & Neuroblastoma Oral Preclinical TBA
HuMab 5B1-ADC Metastatic
Parenteral Preclinical TBA
HuMab 5B1-Radioimmunotherapy Moderate to Severe Pain Metastatic
Parenteral TBA
HuMab 5B1- PET imaging Metastatic
Pancreatic & Colon
Parenteral Phase I Plans to initiate Phase I trials in 2016.
HuMab 5B1- Therapeutic Metastatic
Pancreatic & Colon
Parenteral Phase I Plans to initiate Phase I trials in 2016.


(In $ thousands) 2014 2013
R&D Expenditures
General & Administrative Expenditures
Total Operating Expenses

Contact Information

MabVax Therapeutics, Inc. Key Officers
11588 Sorrento Valley Road, Suite 20 David Hansen, President & CEO
San Diego, CA 92121, USA Gregory P. Hanson, CFO
Phone: 1-858-259-9405 Philip Livingston, MD, CSO
Web: Cathryn Bennett, Director, Clinical Operations

Related posts:
Follow the Money: Trevena, Inc.
Follow the Money: Genocea Biosciences Inc.
Follow the Money: Dynavax Technologies Corporation

Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

More posts by Scotty Chung-Siu